Cheiron raises $8M seed led by Menlo Ventures to model drug programs as software
What's the deal? Cheiron, a Los Altos, California startup building an AI-native operating system for drug development, has raised an $8 million seed round led by Menlo Ventures. Backers include ModernaDealroom has a profile for this one. Try Dealroom → co-founder Robert Langer, former PfizerDealroom has a profile for this one. Try Dealroom → chief medical officer Freda Lewis-Hall, and former Apple AI chief John Giannandrea.
What's the endgame? Cheiron wants to represent an entire drug program — experiments, clinical results, regulatory interactions, and strategic assumptions — as a single connected system. It argues that despite billions invested in drug development, the program itself has never existed as software.
The product: At the center is Cheiron's Life Sciences Knowledge Graph, a layer connecting biomedical, clinical, regulatory, patent, and commercial knowledge into one model. Teams use it across clinical development, regulatory affairs, and competitive intelligence to evaluate programs and make decisions.
Why now? "Advances in AI and knowledge representation have only recently made this possible," the company said. Since launching under six months ago, Cheiron says it has been adopted by tens of thousands of biopharma professionals and deployed by major drug developers.
Early customers include BoryungDealroom has a profile for this one. Try Dealroom →, one of Korea's five largest pharmaceutical companies. "Cheiron helps us move beyond searching across fragmented sources toward understanding the full state of a program," said chief executive officer Jung Gyun Kim.
The signal: The round reflects growing investor conviction that AI can restructure how drug developers connect and reason over scattered evidence, not just search it. Cheiron is betting that a shared model of a program's state — what is known, assumed, and decided — becomes the layer teams build decisions on.
Read more: GlobeNewswire · Wowtale · Yahoo Finance
Image credit: Cheiron
